glp-1 and kidney Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus chronic disease: an approach for the nephrologist GLP-1 agonists in the treatment
Description
In more recent years, the role of this peptide beyond metabolism has progressively been explored, including its impact on kidney physiology and kidney clinical outcomes in people with obesity with or without diabetes
They understand that side effects can and do occur and are there to encourage and support management
95% CI: 0.620.88)
Most patients find that any initial discomfort is manageable and improves significantly after the first 12 weeks, with the therapeutic benefits becoming more apparent over the following months
No two people are the same, so the company provides access to personalized care designed for results
